Title: The Promising Combination of Targeted Therapy and Hormone Therapy for Early-Stage Breast Cancer
Additional Piece: Advancing Treatment Options for Breast Cancer Patients
Breast cancer remains one of the most prevalent forms of cancer among women in the United States. However, recent research presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting offers promising results for women with early-stage hormone receptor-positive/HER2-negative breast cancer.
The study focuses on the use of a targeted therapy drug called ribociclib, which specifically targets genes that allow cancer cells to thrive. When combined with hormone therapy, ribociclib has shown positive outcomes in terms of prolonging symptom-free periods and reducing the risk of cancer recurrence.
I. Ribociclib: A Breakthrough in Breast Cancer Treatment
– Ribociclib, a CDK4/6 inhibitor, works by stopping the growth of cancer cells.
– The FDA has approved ribociclib for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
– The drug is used in combination with an aromatase inhibitor to lower estrogen levels in premenopausal women and with fulvestrant in postmenopausal women.
II. Study Findings and Patient Outcomes
– Approximately 5,000 patients with stage IIA, IIB, or III HR-positive, HER2-negative breast cancer participated in the study.
– Patients were randomly assigned to receive ribociclib with hormone therapy or hormone therapy alone.
– The ribociclib group experienced a 25% lower risk of cancer recurrence compared to the hormone therapy-only group.
– The cancer recurrence rate was 7.4% in the ribociclib group and 9.2% in the hormone therapy-only group.
– Patients who received combination therapy achieved a 3-year cancer remission rate of around 90%, compared to just over 87% for those treated with hormone therapy alone.
III. Long-Term Benefits and New Treatment Options
– Ribociclib demonstrated better overall survival rates and longer periods without signs and symptoms of cancer.
– Medical experts believe that adding ribociclib to endocrine therapy after surgery could decrease the risk of recurrence and improve survival.
– Another CDK4/6 inhibitor, abemaciclib, has FDA approval for use with hormone therapy, providing breast cancer patients with more treatment options.
IV. Future Outlook and Implications for Breast Cancer Treatment
– While ribociclib shows promise, further research is needed to determine its impact on overall survival rates.
– The approval of ribociclib as a treatment option for early-stage breast cancer would improve patient outcomes and choices.
– Discussing the selection of ribociclib or abemaciclib with patients based on their side-effect profiles and treatment duration can enhance personalized care.
In conclusion, the combination of ribociclib and hormone therapy offers new hope for women with early-stage hormone receptor-positive/HER2-negative breast cancer. The study’s findings highlight the potential for improved symptom-free periods and decreased recurrences, ultimately leading to enhanced survival rates. As the medical community continues to explore and refine targeted therapies, patients with breast cancer now have the opportunity for more personalized and effective treatment options.
Summary:
The combination of ribociclib, a CDK4/6 inhibitor, and hormone therapy has shown promising results in treating hormone receptor-positive/HER2-negative early-stage breast cancer. The addition of ribociclib to standard hormone therapy has been found to extend symptom-free periods and reduce the risk of cancer recurrence. Furthermore, patients who received combination therapy achieved higher rates of cancer remission compared to those treated with hormone therapy alone. The approval of ribociclib as a treatment option for early-stage breast cancer would provide patients with another valuable tool in their fight against cancer.
—————————————————-
| Article | Link |
|---|---|
| UK Artful Impressions | Premiere Etsy Store |
| Sponsored Content | View |
| 90’s Rock Band Review | View |
| Ted Lasso’s MacBook Guide | View |
| Nature’s Secret to More Energy | View |
| Ancient Recipe for Weight Loss | View |
| MacBook Air i3 vs i5 | View |
| You Need a VPN in 2023 – Liberty Shield | View |
June 15, 2023 – A drug that targets specific genes that help cancer cells thrive, when combined with hormone therapy, may help women with a specific type of early-stage breast cancer, according to a new research.
The targeted therapy drug showed success in women with early-stage hormone receptor-positive/HER2-negative breast cancer, according to research presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The study showed that patients who received the drug ribociclib (Kisqali) along with standard hormone therapy were symptom-free for longer after their first cancer treatment, compared with those who received hormone therapy alone.
Also, adding the drug to hormone therapy lowered the risk of the cancer coming back by 25%. Hormone receptor-positive/HER2-negative breast cancer accounts for approximately 65% to 70% of breast cancer cases in the United States, making it the most common subtype.
“The goal of treating early breast cancer is curative, with the hope that patients receiving curative therapy will not have recurrences,” said Dennis Slamon, MD, director of clinical and translational research at the UCLA Comprehensive Cancer Center, who presented the findings at the meeting. “But we know that even with stage II disease, a third of those patients recur, and in stage III disease, more than half recur even 2 to 3 decades later.”
Ribociclib is what is known as a CDK4/6 inhibitor, a drug designed to stop the growth of cancer cells. The FDA has approved it to treat HR-positive, HER2-negative advanced or metastatic breast cancer in premenopausal women along with another drug called an aromatase inhibitor, which is used to lower estrogen levels, or with another drug called an aromatase inhibitor. fulvestrant in postmenopausal women. .
Researchers randomly assigned about 5,000 people with stage IIA, IIB, or III HR-positive, HER2-negative breast cancer who were at risk of their cancer coming back to receive treatment with ribociclib with hormone therapy (2,549 patients) or therapy hormonal alone (2,552 patients).
Over time, the cancer came back in 189 patients in the ribociclib group (7.4% of patients), compared with 237 who used hormone therapy alone (9.2% of patients).
Patients were followed for approximately 34 months, with 20% completing 3 years of treatment with ribociclib and 57% completing 2 years of treatment.
The 3-year cancer remission rates were around 90% for patients who received combination therapy, compared with just over 87% for those treated with hormone therapy alone. The benefits observed in the ribociclib group were generally consistent in other subgroups of patients.
Ribociclib also showed better results in overall survival and time without signs and symptoms of cancer in the long term.
“Patients with [this type of cancer] now they have a new treatment option,” said Sylvia Adams, MD, a medical oncologist and director of the Breast Cancer Center at New York University Langone Perlmutter Cancer Center. “Adding … ribociclib to endocrine therapy after surgery may decrease the risk of recurrence and improve survival.”
Adams, who was not involved in the study, said there is another CDK4/6 inhibitor, abemaciclib, that is FDA-approved for use in conjunction with hormone therapy. “Now we will have a second option, once ribociclib is approved for this indication, and we can decide with patients which of these two drugs to use based on their side effect profiles and/or length of treatment,” she said.
Slamon explained that for overall survival, the “trend is in the right direction,” but longer follow-up is needed to see if ribociclib will make a difference.
https://www.webmd.com/breast-cancer/news/20230602/breast-cancer-drug-iyengar?src=RSS_PUBLIC
—————————————————-